The company reported a stronger-than-expected profit, driven by high demand for its drugs for chronic conditions such as diabetes and cardiovascular diseases.
Three private equity funds, namely Chrys Capital, Capital Group, and Everbridge Partners, were reportedly looking to sell stakes worth $592 million in Mankind Pharma via the block deal.
